{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T18:01:17Z","timestamp":1784916077807,"version":"3.55.0"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,24]]},"DOI":"10.7759\/cureus.113315","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T17:21:31Z","timestamp":1784913691000},"source":"Crossref","is-referenced-by-count":0,"title":["Real-World Survival Outcomes of Glioblastoma Patients Under Universal Temozolomide Access in Uruguay: A Retrospective Cohort Study (2009\u20132018) and Implications for Health Policy"],"prefix":"10.7759","author":[{"given":"Maria","family":"Massia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robinson","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Ximenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp R","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, et al.. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005, 352:987-96. 10.1056\/NEJMoa043330","journal-title":"N Engl J Med"},{"key":"ref2","unstructured":"Fondo Nacional de Recursos (FNR). Normativa de cobertura: tratamiento sist\u00e9mico de tumores del sistema nervioso central con temozolomida [Internet]. (2026). Accessed: July 5, 2026: https:\/\/www.fnr.gub.uy\/wp-content\/uploads\/2012\/08\/n_trat_tumores_snc.pdf."},{"key":"ref3","article-title":"Glioblastoma multiforme cerebral hemisf\u00e9rico: an\u00e1lisis de sobrevida de 65 casos tratados en el Departamento de Oncolog\u00eda del Hospital de Cl\u00ednicas, desde 1980 a 2000","volume":"28","author":"Rodr\u00edguez R","year":"2012","unstructured":"Rodr\u00edguez R, Lombardo K, Rold\u00e1n G, Silvera J, Lagomarsino R. Glioblastoma multiforme cerebral hemisf\u00e9rico: an\u00e1lisis de sobrevida de 65 casos tratados en el Departamento de Oncolog\u00eda del Hospital de Cl\u00ednicas, desde 1980 a 2000. Rev Med Urug. 2012, 28:250-61.","journal-title":"Rev Med Urug"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary","volume":"131","author":"Louis DN","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, et al.. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016, 131:803-20. 10.1007\/s00401-016-1545-1","journal-title":"Acta Neuropathol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi HA","year":"2022","unstructured":"Tawbi HA, Schadendorf D, Lipson EJ, et al.. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022, 386:24-34. 10.1056\/NEJMoa2109970","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown CE","year":"2016","unstructured":"Brown CE, Alizadeh D, Starr R, et al.. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med. 2016, 375:2561-9. 10.1056\/NEJMoa1610497","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac202","article-title":"CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019","volume":"24","author":"Ostrom QT","year":"2022","unstructured":"Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019. Neuro Oncol. 2022, 24:v1-v95. 10.1093\/neuonc\/noac202","journal-title":"Neuro Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/517769-real-world-survival-outcomes-of-glioblastoma-patients-under-universal-temozolomide-access-in-uruguay-a-retrospective-cohort-study-2009-2018-and-implications-for-health-policy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T17:21:31Z","timestamp":1784913691000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/517769-real-world-survival-outcomes-of-glioblastoma-patients-under-universal-temozolomide-access-in-uruguay-a-retrospective-cohort-study-2009-2018-and-implications-for-health-policy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":7,"URL":"https:\/\/doi.org\/10.7759\/cureus.113315","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,24]]}}}